Association between plasma sLOX-1 concentration and arterial stiffness in middle-aged and older individuals

Takeshi Otsuki,¹* Seiji Maeda,² Jun Mukai,³ Makoto Ohki,² Mamoru Nakanishi⁴ and Toshikazu Yoshikawa⁵

¹Faculty of Sport and Health Sciences, Ryutsu Keizai University, 120 Ryugasaki, Ibaraki 301-8555, Japan
²Faculty of Health and Sport Sciences, University of Tsukuba, 1-1 Tennoudai, Tsukuba, Ibaraki 305-8577, Japan
³Biomarker Science Co., Ltd., 103-5 Tanaka Monzen-cho, Sakyo-ku, Kyoto 606-8225, Japan
⁴Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
⁵Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan

E-mail: takeshi.otsuki17@gmail.com
*To whom correspondence should be addressed.

(Received 15 February, 2015; Accepted 6 May, 2015; Published online 30 July, 2015)

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is implicated in vascular endothelial function. Vascular endothelial function is a potent regulator of arterial stiffness, an independent risk factor for cardiovascular disease. However, it is unknown whether LOX-1 is associated with arterial stiffness. Plasma concentrations of soluble LOX-1 (sLOX-1) and brachial-ankle pulse wave velocity (baPWV, an index of arterial stiffness) were measured in 143 individuals between 51 and 83 years of age. Plasma sLOX-1 concentration was correlated with baPWV (r = 0.288, p = 0.0005). In stepwise regression analysis, plasma sLOX-1 concentration was associated with baPWV, after adjusting for age; body mass index; blood pressure; heart rate; blood levels of cholesterol, triglycerides, glucose, hemoglobin A1c, and insulin; sex; and use of antihypertensives, lipid-lowering agents, and other medications (R² = 0.575, p < 0.0001). Multiple logistic regression demonstrated that plasma sLOX-1 concentration was independently associated with elevated baPWV (≥14.0 m/s; odds ratio, 1.01; 95% confidence interval, 1.00–1.03; p = 0.03). These results suggest that LOX-1 is associated with arterial stiffness.

Key Words: age, arterial stiffness, lectin-like oxidized low-density lipoprotein receptor-1, pulse wave velocity

Central arteries such as the aorta and the carotid artery have elastic properties that buffer the pulsations in blood pressure and blood flow via wall extension. Arterial stiffness increases with age.⁶ Increased arterial stiffness (i.e., decreased buffering function) is a well-established cardiovascular risk factor.⁷ Structural factors such as elastin and collagen content in the arterial media are implicated in arterial stiffness. In addition, functional factors (e.g., endothelial function and sympathetic nervous system activity) play a role in regulation of arterial stiffness. Increased oxidative stress and decreased anti-oxidant capacity are functional factors for arterial stiffening. Brinkley et al.⁸ reported that plasma oxidized low-density lipoprotein (oxLDL) levels are independently associated with arterial stiffness. However, the mechanisms underlying the oxLDL-related arterial stiffening have not been fully elucidated.

Lectin-like oxLDL receptor-1 (LOX-1) is the major receptor for oxLDL on the surface of endothelial cells.⁹ Circulating levels of soluble LOX-1 (sLOX-1) have been investigated as a predictor of coronary and peripheral artery disease.⁴ Animal studies have suggested that upregulation of LOX-1 reduces endothelium-dependent vasodilatation via decreased nitric oxide (NO) availability.⁹ In addition, a human study demonstrated that circulating levels of sLOX-1 are correlated with endothelial NO synthase (NOS) activity.¹⁰ NO is a potent regulator of arterial stiffness.¹¹ However, it is unknown whether LOX-1 is related to arterial stiffness. The aim of this study was to investigate whether plasma concentrations of sLOX-1 are associated with arterial stiffness in middle-aged and older individuals.

Materials and Methods

Participants. Measurements were performed in 154 individuals. Smokers and premenopausal women were excluded from the analysis because both smoking and menstrual cycle affect arterial stiffness.¹²,¹³ The remaining 143 individuals, between the ages of 51 and 83 years, were analysed. Subjects were divided into two groups based on brachial-ankle pulse wave velocity (baPWV), an index of arterial stiffness: low (<14.0 m/s) or high (≥14.0 m/s, Table 1).¹⁴,¹⁵ Subjects refrained from alcohol consumption and intense physical activity starting the day before testing, and caffeine consumption on the day of testing.

This study was approved by the Ethics Committee of Ryutsu Keizai University (Approval Number 1) and complied with the principles of the Helsinki Declaration. All participants gave their written informed consent prior to study participation.

BaPWV assessment. After a resting period of at least 20 min, baPWV was measured as in our previous studies.¹⁶,¹⁷ Briefly, brachial and post-tibial artery pressure waveforms were obtained simultaneously in duplicate with cuffs connected to an air plethysmographic sensor and an oscillometric pressure sensor (formPW/ABI; Omron Colin, Tokyo, Japan). The distance traveled by the pulse wave from the heart to the brachial recording site (Distance A) and that from the heart to the post-tibial recording site (Distance B) were calculated based on each subject’s height. The time it took from when the pulse wave reached the brachial recording site to when it reached the post-tibial recording site (T) was determined based on the time delay between the brachial and post-tibial ‘foot’ waveforms. BaPWV was calculated as the difference between Distance A and B divided by T. Our representative day-to-day coefficient of variation (CV) for baPWV was 2.2 ± 1.3%.¹⁶

Blood chemical analysis. Blood samples were collected in the morning after an overnight fast. Plasma sLOX-1 concentrations were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) with two specific monoclonal antibodies against sLOX-1, with recombinant sLOX-1 as the assay standard.

doi: 10.3164/jcbn.15-27
©2015 JCBN

J. Clin. Biochem. Nutr. | September 2015 | vol. 57 | no. 2 | 151–155
In our laboratory, intra-assay and inter-assay CVs for blood sLOX-1 concentration were 1.6–5.2% and 3.9–7.7%, respectively.\(^{(5)}\)

Serum concentrations of low- and high-density lipoprotein cholesterol (LDL and HDL, respectively) and triglycerides were measured by using commercial enzymatic kits (Cholestest\textsuperscript{\textregistered} LDL; Sekisui Medical, Tokyo, Japan; Determiner L HDL-C or Metabo-Lead HDL-C; Kyowa Medex, Tokyo, Japan; and Determiner C-TG; Kyowa Medex) and an autoanalyzer (JCA-BM 8060; JEOL, Tokyo, Japan). Plasma glucose concentrations and haemoglobin A1c were determined by using a enzymatic kit (L-type Wako Glu2; Wako Pure Chem. Ind., Osaka, Japan), a latex agglutination kit (Determiner L HbA1c, Kyowa Medex), and an autoanalyzer (JCA-BM 9130; JEOL). Serum insulin levels were assessed by an electrochemiluminescence immunoassay by using an analyzer (E170; Roche Diagnostics K.K., Tokyo, Japan) and the designated reagents.

**Statistical analysis.** Results are given as means ± SE. The unpaired \(t\) test or chi-squared test was used to detect differences between groups, as appropriate. Relationships between two variables were investigated using Pearson’s simple correlation analysis. Stepwise and logistic regression were used to identify independent predictors. \(P\) values <0.05 were considered statistically significant.

**Results**

BaPWV was correlated with plasma sLOX-1 concentration (Fig. 1), age (\(r = 0.466, p < 0.0001\)), systolic blood pressure (SBP; \(r = 0.615, p < 0.0001\)), diastolic blood pressure (DBP; \(r = 0.102, p < 0.0001\)), heart rate (HR; \(r = 0.238, p = 0.004\)), plasma glucose concentration (\(r = 0.274, p = 0.0009\)), and hemoglobin A1c (\(r = 0.261, p = 0.001\)). BaPWV was not correlated with body mass index (BMI) and serum concentrations of LDL, HDL, triglycerides, and insulin. Plasma sLOX-1 concentration, age, SBP, and HR were identified as independent predictors of baPWV in the stepwise regression analysis that included sex (male = 0, female = 1); use of antihypertensive medications, lipid-lowering agents, and other medications (yes = 0, no = 1); age; BMI; SBP; DBP; HR; and blood levels of sLOX-1, LDL, HDL, triglycerides, glucose, hemoglobin A1c, and insulin (Table 2).

Plasma sLOX-1 concentrations, proportion of subjects on antihypertensive medications, age, SBP, and DBP were higher in the high baPWV group than in the low baPWV group (Table 1). Serum LDL concentrations were lower in the high baPWV group compared to the low baPWV group. Multiple logistic regression analysis demonstrated that plasma sLOX-1 concentration, age, SBP, and HR were associated with baPWV, independent of other factors (Table 3).

Age was correlated with plasma sLOX-1 levels (Fig. 2). Correlation coefficients between age and plasma sLOX-1 concentration were comparable between the low (\(r = 0.232, p = 0.20\)) and high (\(r = 0.229, p = 0.01\)) baPWV groups although the coefficient in the low baPWV group did not reach statistical significance because of the small sample size.
Discussion

First, plasma sLOX-1 concentration was correlated with baPWV. In stepwise regression analysis, plasma sLOX-1 concentration was associated with baPWV, after adjusting for sex; use of antihypertensive medication (yes = 0, no = 1), use of lipid-lowering agent (yes = 0, no = 1), use of other medications (yes = 0, no = 1), body mass index (kg/m²), diastolic blood pressure (mmHg), low-density lipoprotein cholesterol (mg/dl), high-density lipoprotein cholesterol (mg/dl), triglycerides (mg/dl), glucose (mg/dl), hemoglobin A1c (%), insulin (μU/dl), sLOX-1, soluble lectin-like oxidized low-density lipoprotein receptor-1.

This study chose 14.0 m/s as cutoff value to divide subjects into the low or high baPWV group. Munakata et al. (14) reported that higher baPWV (≥14.0 m/s) was an independent risk factor for microalbuminuria after two years in 321 hypertensive patients. Logistic regression analysis in 10,828 healthy subjects showed that baPWV >14.0 m/s was independently associated with higher risk based on the Framingham score and the presence of atherosclerotic cardiovascular disease. (15) On the other hand, recent studies have proposed a higher cutoff baPWV value. Turin et al. (18) demonstrated that risk of all-cause mortality was higher in the highest baPWV group (≥17.0 m/s) relative to the lowest baPWV group (<14.0 m/s) in 2,642 individuals without a

Table 2. Stepwise regression analysis to identify independent predictors of arterial stiffness (brachial-ankle pulse wave velocity)

| Independent predictors (n = 143, R² = 0.575, p<0.0001) | Regression coefficient | SE | β | p value |
|--------------------------------------------------------|------------------------|----|---|---------|
| Constant                                               | -1427.5                | 254.5 | 0.001 | <0.001 |
| Systolic blood pressure (mmHg)                         | 9.9                    | 1.0   | 0.557 | <0.001 |
| Age (years)                                            | 14.8                   | 2.9   | 0.299 | <0.001 |
| Heart rate (bpm)                                       | 10.1                   | 2.2   | 0.248 | <0.001 |
| sLOX-1 (ng/L)                                          | 0.3                    | 0.1   | 0.120 | 0.04    |

Excluded variables: sex (male = 0, female = 1), use of antihypertensive medication (yes = 0, no = 1), use of lipid-lowering agent (yes = 0, no = 1), use of other medications (yes = 0, no = 1), body mass index (kg/m²), diastolic blood pressure (mmHg), low-density lipoprotein cholesterol (mg/dl), high-density lipoprotein cholesterol (mg/dl), triglycerides (mg/dl), glucose (mg/dl), hemoglobin A1c (%), insulin (μU/dl). sLOX-1, soluble lectin-like oxidized low-density lipoprotein receptor-1.

Table 3. Odds ratios for increased arterial stiffness (brachial-ankle pulse wave velocity ≥14.0 m/s)

| Univariate | Multivariate |
|------------|--------------|
|            | Odds ratio   | (95% CI) | p value | Odds ratio   | (95% CI) | p value |
| sLOX-1     | 1.01         | (1.00–1.02)| 0.004 | 1.01         | (1.00–1.03)| 0.03   |
| Sex        | 1.20         | (0.47–3.09)| 0.69 | 6.27         | (0.62–63.44)| 0.12   |
| Antihypertensive use | 4.64      | (1.32–16.25)| 0.01 | 4.69         | (0.45–49.10)| 0.19   |
| Lipid-lowering agent use | 5.61     | (0.72–43.87)| 0.10 | 5.84         | (0.08–416.44)| 0.41   |
| Other medication use | 0.92     | (0.40–2.08)| 0.83 | 0.49         | (0.10–2.42)| 0.37   |
| Age        | 1.25         | (1.14–1.36)| <0.0001 | 1.31         | (1.07–1.60)| 0.009  |
| Body mass index | 0.98      | (0.85–1.13)| 0.75 | 0.81         | (0.58–1.13)| 0.21   |
| Systolic blood pressure | 1.13     | (1.08–1.19)| <0.0001 | 1.40         | (1.16–1.69)| 0.0005 |
| Diastolic blood pressure | 1.10     | (1.04–1.16)| 0.0005 | 0.87         | (0.72–1.04)| 0.12   |
| Heart rate | 1.05         | (1.00–1.11)| 0.05 | 1.18         | (1.03–1.34)| 0.01   |
| LDL        | 0.98         | (0.97–1.00)| 0.02 | 1.00         | (0.96–1.03)| 0.77   |
| HDL        | 0.99         | (0.97–1.01)| 0.48 | 1.00         | (0.94–1.05)| 0.86   |
| Triglycerides | 1.02      | (0.99–1.02)| 0.19 | 1.00         | (0.97–1.02)| 0.88   |
| Glucose    | 1.02         | (0.99–1.05)| 0.29 | 0.92         | (0.82–1.03)| 0.16   |
| Hemoglobin A1c | 1.56      | (0.68–3.58)| 0.29 | 0.10         | (0.81–278.39)| 0.15   |
| Insulin    | 1.11         | (0.96–1.29)| 0.14 | 1.22         | (0.80–1.88)| 0.36   |

CI, confidence interval; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; sLOX-1, soluble lectin-like oxidized low-density lipoprotein receptor-1.

Fig. 2. Correlation between age and plasma concentration of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1).
early and advanced stages of atherosclerosis. Miyano et al. documented that baPWV ≥18.0 m/s was associated with an increased risk of three-year total cardiovascular mortality in 530 normotensive and hypertensive subjects. Based on these and other previous studies, guidelines for non-invasive vascular function testing by the Japanese Circulatory Society in 2013 defined baPWV of 14.0 m/s as indicative of cardiovascular risk, which was associated with recommendations for lifestyle modification, and 18.0 m/s as a marker of organ dysfunction. When the present subjects were categorized according to a baPWV cutoff of 18.0 m/s, an independent association between plasma sLOX-1 concentration and baPWV was not detected (data not shown). In a previous study by Kataoka et al., carotid arterial endothelial cells covering early atherosclerotic lesions were more frequently positive for LOX-1 expression (71.4%) relative to those in advanced atherosclerotic lesions (33.3%). LOX-1 may be implicated in the early stage of arterial stiffening rather than its more advanced stages.

The correlation coefficient between baPWV and plasma sLOX-1 concentration was lower than between baPWV and age, SBP, and HR. First, there seems to be difference in role of LOX-1 between early and advanced stages of atherosclerosis. This difference may be associated with the lower correlation coefficient. Unfortunately, the sample size in the low baPWV group was insufficient to test this hypothesis. It is an important next step. Second, LOX-1 is possibly associated with baPWV via NO and other factors although SBP and HR directly participate in regulation of baPWV. There is an unequivocal interaction between blood pressure and arterial stiffness; elevated blood pressure increases arterial stiffness and vice versa. Progressive increases in HR caused by pacing were accompanied by progressive increases in elastic arterial stiffness. Finally, plasma sLOX-1 concentrations were used as a surrogate marker of LOX-1 expression in the vascular endothelium although age, SBP and HR were directly measured. However, this study demonstrated that plasma sLOX-1 concentrations correlate well with LOX-1 expression in the vascular endothelium. As pointed out in the Editorial by Brown et al., plasma sLOX-1 levels may be influenced by LOX-1—regulating enzymes, forces that release LOX-1 from the cell surface, sLOX-1 clearance, and other factors. Further studies are warranted to elucidate the role of LOX-1 in the stiffening of large arteries.

In conclusion, the present results suggest that LOX-1 is related to arterial stiffness in middle-aged and older individuals.

Acknowledgments

This work was supported by the Nakatomi Foundation, JSPS KAKENHI Grant Number 23650437, and the Uehara Memorial Foundation. We thank Ryugasaki City for supporting our study based on a partnership agreement between Ryugasaki City and Ryutsu Keizai University (Ryu Ryu Renkei).

Abbreviations

ACh acetylcholine
baPWV brachial-ankle pulse wave velocity
BMI body mass index
CI confidence interval
CV coefficient of variation
DBP diastolic blood pressure
ELISA enzyme-linked immunosorbent assay
HDL high-density lipoprotein cholesterol
HR heart rate
LDL low-density lipoprotein cholesterol
LOX-1 lectin-like oxidized low-density lipoprotein receptor-1
NO nitric oxide
NOS nitric oxide synthase
oxLDL oxidized low-density lipoprotein
SBP systolic blood pressure
sLOX-1 soluble lectin-like oxidized low-density lipoprotein receptor-1

References

1 Tomiyama H, Yamashina A, Arai T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 2003; 166: 303–309.
2 Vlachopoulos C, Aznauridis K, Terentes-Printzios D, Ioakeimidis N, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis.
Hypertension 2012; 60: 556–562.
3 Brinkley TE, Nicklas BJ, Kanaya AM, et al. Plasma oxidized low-density lipoprotein levels and arterial stiffness in older adults: the health, aging, and body composition study. Hypertension 2009; 53: 846–852.
4 Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997; 386: 73–77.
5 Fukui M, Tanaka M, Senmaru T, et al. LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes. Metabolism 2013; 62: 935–938.
6 Inoue N, Okamura T, Kokubo Y, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 2010; 56: 550–558.
7 Eichhorn B, Muller G, Leuner A, Sawamura T, Ravens U, Morawietz H. Impaired vascular function in small resistance arteries of LOX-1 over-expressing mice on high-fat diet. Cardiovasc Res 2009; 82: 493–502.
8 Xu X, Gao X, Potter BJ, Cao JM, Zhang C. Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 871–877.
9 Yavuzer S, Yavuzer H, Cengiz M, et al. Endothelial damage in white coat hypertension: role of lectin-like oxidized low-density lipoprotein-1. J Hum Hypertens 2015; 29: 92–98.
10 Sugawara J, Komine H, Hayashi K, et al. Effect of systemic nitric oxide synthase inhibition on arterial stiffness in humans. Hypertens Res 2007; 30: 411–415.
11 Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002; 53: 189–192.
12 Hayashi K, Miyachi M, Seno N, et al. Variations in carotid arterial compliance during the menstrual cycle in young women. Exp Physiol 2006; 91: 465–472.
13 Stefanadis C, Tsianis E, Vlachopoulos C, et al. Unfavorable effect of smoking on the elastic properties of the human aorta. Circulation 1997; 95: 31–38.
14 Munakata M, Miura Y, Yoshinaga K; J-TOPP study group. Higher brachial-ankle pulse wave velocity as an independent risk factor for future microalbuminuria in patients with essential hypertension: the J-TOPP study. J Hypertens 2009; 27: 1466–1471.
15 Yamashina A, Tomiyama H, Arai T, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26: 615–622.
16 Otsuki T, Takanami Y, Aoi W, Kawai Y, Ichikawa H, Yoshikawa T. Arterial stiffness acutely decreases after whole-body vibration in humans. Acta Physiol (Oxf) 2008; 194: 189–194.
17 Otsuki T, Shimizu K, Ienitmu S, Kono I. Multicomponent supplement containing Chlorella decreases arterial stiffness in healthy young men. J Clin Biochem Nutr 2013; 53: 166–169.
18 Turin TC, Kita Y, Rumana N, et al. Brachial-ankle pulse wave velocity predicts all-cause mortality in the general population: findings from the Takashima study, Japan. Hypertens Res 2010; 33: 922–925.
19 Miyano I, Nishinaga M, Takata J, et al. Association between brachial-ankle pulse wave velocity and 3-year mortality in community-dwelling older adults. Hypertens Res 2010; 33: 678–682.
20 Kataoka H, Kume N, Miyamoto S, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999; 99: 3110–3117.
21 Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1996; 14: 897–901.
22 Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 2013; 70: 2859–2872.
23 Jono T, Miyazaki A, Nagai R, Sawamura T, Kimamura T, Horiechi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002; 511: 170–174.
24 Anuarad E, Enkhmaa B, Gungor Z, et al. Age as a modulator of inflammatory cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2011; 31: 2151–2156.
25 Nagai R, Shirakawa J, Fujiwara Y, et al. Detection of AGEs as markers for carbohydrate metabolism and protein denaturation. J Clin Biochem Nutr 2014; 55: 1–6.
26 Pirillo A, Catapano AL. Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseases. Dis Markers 2013; 35: 413–418.
27 Kobayashi N, Hata N, Kume N, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 as an early biomarker for ST elevation myocardial infarction: time-dependent comparison with other biomarkers. Circ J 2011; 75: 1433–1439.
28 Brinkley TE, Kume N, Mitsuoka H, Phares DA, Hagberg JM. Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women. Obesity (Silver Spring) 2008; 16: 1454–1456.
29 Brown J, Nallamshetty S, Putzky J. Intersecting vectors of basic science research and clinical medicine: LOX-1? Clin Chem 2010; 56: 499–501.